FindMyKOL
Clinical trialNCT02049866CompletedPhase 2Interventional

Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

NCT02049866 is a phase 2 interventional trial sponsored by Elizabeth Shane. As of 21 Nov 2026, it is completed. It studies Denosumab in Adult Idiopathic Generalized Osteoporosis. The registry lists an enrollment of 33 participants at 2 sites in 1 country. The registry lists a start date of 19 Nov 2014 and a primary completion date of 31 Mar 2020.

SponsorElizabeth ShaneEnrollment33Adult Idiopathic Generalized Osteoporosis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT02049866
FieldValue
Registry IDNCT02049866
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorElizabeth Shane
Enrollment33
Registered sites2
Countries1
ConditionsAdult Idiopathic Generalized Osteoporosis
DrugsDenosumab
Start19 Nov 2014
Primary completion31 Mar 2020
Study completion23 Dec 2021
Last update posted12 Dec 2022

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research study is to evaluate antiresorptive therapy with denosumab (Prolia) for prevention of bone loss after stopping teriparatide (TPTD) in premenopausal women with idiopathic osteoporosis. Premenopausal women who have received TPTD in the FDA Orphan Diseases Program-funded trial, "A Phase 2 Study of Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women" (NCT01440803) may be eligible to participate in the current study, a 36-month open-label pilot study of denosumab (Prolia®, 60mg subcutaneous (SC) every 6 months). The goals of the study are to estimate the effects of denosumab on central and peripheral, as well as trabecular and cortical, bone mass and microstructure and to obtain preliminary data to inform the design of a future randomized study. This study presents the first opportunity to study the effects of denosumab after TPTD in this unique and severely affected group of young women. Funding Source: FDA Office of Orphan Products Development (OOPD).

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Nebraska, United States1 site
  • Creighton University

    Omaha

New York, United States1 site
  • Columbia University Medical Center

    New York

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 1 siteNY1MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraska: 1 siteNE1MissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT02049866

Each answer restates registry values shown on this page.

What is NCT02049866?

NCT02049866 is a phase 2 interventional trial sponsored by Elizabeth Shane. It studies Denosumab in Adult Idiopathic Generalized Osteoporosis.

Who leads NCT02049866?

The registry names Adi Cohen, MD (principal investigator, Columbia University) and Elizabeth Shane, MD (principal investigator, Columbia University) as overall officials.

Where does NCT02049866 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT02049866 study?

The registered drug and biological interventions are Denosumab.

When did NCT02049866 end?

The registry lists a primary completion date of 31 Mar 2020 and a study completion date of 23 Dec 2021. The sponsor last updated the record on 12 Dec 2022.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.